Belimumab, Azathioprine Did Not Lower Risk for Relapse in ANCA-Associated Vasculitis

Belimumab, Azathioprine Did Not Lower Risk for Relapse in ANCA-Associated Vasculitis

Belimumab in combination with glucocorticoids and azathioprine did not lower the risk for relapse in patients with antineutrophil cytoplasm antibody-associated vasculitis.

Mycophenolate Mofetil Noninferior to Cyclophosphamide in ANCA-Associated Vasculitis

Mycophenolate Mofetil Noninferior to Cyclophosphamide in ANCA-Associated Vasculitis

Mycophenolate mofetil was noninferior to cyclophosphamide for remission induction, but resulted in higher rates of relapse.

Survival Predictors Identified in Patients With Biopsy-Proven Giant Cell Arteritis

Survival Predictors Identified in Patients With Biopsy-Proven Giant Cell Arteritis

Researchers evaluated the influence of disease-related findings and treatment outcomes on survival in a population-based cohort of patients with giant cell arteritis.

IgA Vasculitis Associated With Increased Risk for Hypertension, Chronic Kidney Disease

IgA Vasculitis Associated With Increased Risk for Hypertension, Chronic Kidney Disease

Patients with immunoglobulin A-associated vasculitis were at increased risk for hypertension and chronic kidney disease.

Vaccinations Not Linked to Childhood-Onset IgA Vasculitis

Vaccinations Not Linked to Childhood-Onset IgA Vasculitis

Vaccinations most frequently administered to children did not increase the risk for IgA vasculitis onset during the 3 months post-vaccination.

Rituxan Labeling Updated With Follow-Up Treatment Info for Patients With GPA/MPA

Rituxan Labeling Updated With Follow-Up Treatment Info for Patients With GPA/MPA

The FDA has approved updated labeling for Rituxan to include information on follow up treatment for patients with GPA and MPA who have achieved disease control with induction therapy.

Giant Cell Arteritis: Examining Challenges in Diagnosis and Treatment

Giant Cell Arteritis: Examining Challenges in Diagnosis and Treatment

Improved biomarkers are needed to monitor disease activity effectively in giant cell arteritis.

Improved Immune Response to Pneumococcal Vaccine in ANCA-Associated Vasculitis

Improved Immune Response to Pneumococcal Vaccine in ANCA-Associated Vasculitis

Suppressing cytomegalovirus may improve the immune response to a T cell-dependent pneumococcal vaccination in patients experiencing ANCA-associated vasculitis.

Granulomatosis With Polyangiitis Linked to Altered Nasal Microbial Composition

Granulomatosis With Polyangiitis Linked to Altered Nasal Microbial Composition

Granulomatosis with polyangiitis was associated with an altered nasal microbial composition at both the bacterial and the fungal levels.

Examining Risk for Severe Infection in Rituximab-Treated AAV

Examining Risk for Severe Infection in Rituximab-Treated AAV

Researchers observed severe infections in one-quarter of patients with AAV receiving rituximab.

Sign Up for Free e-newsletters